Are you using Tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroencocrine tumors of GI (non-lung) origins?  

Is it  your preferred second line therapy for metastatic  small cell (non lung primary)  that has progressed on chemo immunotherapy ( Carboplatin , Etoposide, and Atezolizumab) who are platinum resistant (progressed less than 6 months) ?